Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a universal and flexible Digital PCR solution.
Discover the simplicity of Digital PCR with the Naica System: a unique fast, easy-to-use, versatile and reliable 3-color multiplexing capability!
Address1 Mail du Professeur Georges Mathé
Philips-led consortium awarded 6.3 M€ H2020 grant, Stilla to develop high-plex liquid biopsy panels with new multi-color dPCR system.23 Nov 2017 Stilla Technologies
Stilla is proud to be part of a Philips-led consortium that has been awarded a Horizon 2020 EU research grant totalling EUR 6.3 million to develop integrated approaches for personalized cancer treatment.
The four-year research project, ‘Liquid biopsies and IMAging for improved cancer care’ (LIMA), aims to increase the accuracy of both genetic and functional characterization of primary breast cancer and rectal cancer by combining two diagnostic technologies: advanced blood tests called liquid biopsy and Magnetic Resonance Imaging (MRI). The clinical research studies will be carried out at the University Medical Center of Utrecht (UMC Utrecht) in the Netherlands, and the Institut National de la Sante et de la Recherche Medicale in France (INSERM).